Hospitalization in Patients with Psoriasis: Impact of Biological Therapies on Temporal Evolution
February 2021 | Volume 20 | Issue 2 | Original Article | 208 | Copyright © February 2021
Published online January 11, 2021
Queila Rodriguez-Jato MDa, Alessia Ruibal Pereira a, Ana Batalla MD PhDa, Maria Teresa Abalde MDa, Laura Salgado-Boquete MDa, Crisitina Martinez-Reglero b, Virginia Fernández-Redondo MD PhDa, Angeles Florez MD PhDa
aComplejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
bInstituto de Investigación Sanitaria Galicia Sur (IISGS), Alvaro Cunqueiro Hospital,Vigo, Pontevedra, Spain
Objective: In this study, we aimed to describe the temporal evolution of the hospitalizations of patients with psoriasis throughout the period between eight years before the commercialization of the first biological drugs and present, and secondly, whether this market irruption was related to a decrease in the number of admissions.
Methods: Data was collected retrospectively from the Dermatology department of the Complexo Hospitalario Universitario de Ponte- vedra (CHUP) including patients of all ages with a diagnosis of psoriasis and at least one admission to the department of Dermatology along the study period. We established different time periods for comparing the average hospitalizations per 100,000 inhabitants-year and the average stay, considering that the first biologic drug marketed for the treatment of psoriasis was in 2004.
Results: Regression models indicated a significant change in the temporal trend of the hospitalization rate per 100,000 inhabitants-year starting in 2004. In all cases, a gradual and significant decrease in the number of admissions per 100,000 inhabitants-year and in the average hospitalization rate per psoriasis per 100,000 inhabitants-year along the study period were found. There was also a significant decrease in medical hospitalizations and medical hospitalizations excluding psoriasis throughout the study period.
Conclusions: In our study population hospitalizations for psoriasis descended progressively and significantly from 2004. So far there are no extensive data on the impact of biological therapies on psoriasis hospitalization.
J Drugs Dermatol. 2021;20(2):208-214. doi:10.36849/JDD.2021.4931